Skip to content

Greenwich LifeSciences, Inc.

GLSI · XNAS

CIK 1799788fmd_0SAF208GCYH6SBW6SMWBXVEDGBManufacturing · Pharmaceutical PreparationsTemplate: Standard

Coverage: Jan 01, 2019 to Jun 30, 2026, 30 periods

Income Statement · Annual · Millions · USD
Line itemFY2019FY2020FY2021FY2022FY2023FY2024FY2025
Research and development314681517
Total operating expenses325891819
Operating income(3)(2)(5)(8)(9)(18)(19)
Interest and investment income–000000
Net income(3)(2)(5)(8)(9)(17)(19)
Greenwich LifeSciences, Inc. (GLSI) financial statements · FinancialMD